125 related articles for article (PubMed ID: 32604118)
1. Whole-Body 177Lu-Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient.
Askari E; Moghadam SZ; Divband G; Aryana K
Clin Nucl Med; 2020 Oct; 45(10):805-807. PubMed ID: 32604118
[TBL] [Abstract][Full Text] [Related]
2. 177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
Aryana K; Zarehparvar Moghadam S; Salek R; Divband G
Clin Nucl Med; 2018 Apr; 43(4):273-275. PubMed ID: 29401146
[TBL] [Abstract][Full Text] [Related]
3. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
7. Exceptional 4-year response to
Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
[No Abstract] [Full Text] [Related]
8. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
10. Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177 Lu-Prostate-Specific Membrane Antigen Scan.
Taghavi M; Ahmadi R; Qutbi M
Clin Nucl Med; 2024 May; 49(5):e217-e218. PubMed ID: 38409757
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
[TBL] [Abstract][Full Text] [Related]
12. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
13. Dual 177 Lu-Prostate-Specific Membrane Antigen and 177 Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation.
Beyhan E; Erol Fenercioğlu Ö; Şahin R; Çermik TF; Ergül N
Clin Nucl Med; 2024 May; 49(5):447-448. PubMed ID: 38409763
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Kim YJ; Kim YI
Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
[TBL] [Abstract][Full Text] [Related]
15. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Yadav MP; Ballal S; Bal C; Sahoo RK; Damle NA; Tripathi M; Seth A
Clin Nucl Med; 2020 Jan; 45(1):19-31. PubMed ID: 31789908
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
18. 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
Vatsa R; Sood A; Vadi SK; Das CK; Kaur K; Parmar M; Mittal BR
Clin Nucl Med; 2020 Jun; 45(6):437-438. PubMed ID: 32366786
[TBL] [Abstract][Full Text] [Related]
19. Effect of External Cooling on
Yilmaz B; Nisli S; Ergul N; Gursu RU; Acikgoz O; Çermik TF
J Nucl Med; 2019 Oct; 60(10):1388-1393. PubMed ID: 30850503
[TBL] [Abstract][Full Text] [Related]
20.
Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
